-+ 0.00%
-+ 0.00%
-+ 0.00%

Nicox says China regulator accepts NCX 470 NDA for review

PUBT·09/11/2026 05:30:21
Listen to the news
Nicox says China regulator accepts NCX 470 NDA for review
  • China’s NMPA accepted for review the New Drug Application for Nicox’s NCX 470 glaucoma treatment, filed by licensee Ocumension Therapeutics.
  • Regulatory decision typically takes 12-18 months from submission; review follows an August filing.
  • Nicox has received EUR 18 million in license fees from Ocumension; royalties on sales set at 6%-12%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NicOx SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609110130PRIMZONEFULLFEED1001262175) on September 11, 2026, and is solely responsible for the information contained therein.